Treatment of Acute Gout Flare
For acute gout flares, first-line treatment should be corticosteroids, NSAIDs, or colchicine, with corticosteroids preferred as first-line therapy in patients without contraindications due to their safety profile and low cost. 1
First-Line Medication Options
Corticosteroids
- Preferred first-line option for patients without contraindications 1
- Dosing: Prednisolone 35 mg daily for 5 days 1
- Benefits: As effective as NSAIDs with fewer adverse effects 1
- Contraindications: Systemic fungal infections 1
- Side effects: Mood disorders, elevated blood glucose, immune suppression, fluid retention 1
Colchicine
- Recommended dosing: 1.2 mg at first sign of flare, followed by 0.6 mg one hour later (maximum 1.8 mg over one hour) 2, 3
- Most effective when started within 36 hours of symptom onset 2
- Side effects: Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal pain) 2
- Contraindicated in:
NSAIDs
- Use at full FDA-approved anti-inflammatory doses until attack resolves 2
- No evidence that any specific NSAID (including indomethacin) is superior 1
- Contraindications: Renal disease, heart failure, cirrhosis, history of GI bleeding 2
- Side effects: Dyspepsia, GI perforations, ulcers, bleeding 1
Patient-Specific Treatment Algorithm
For patients without contraindications:
- Corticosteroids (prednisolone 35 mg for 5 days) as first-line therapy 1
For patients with cardiovascular disease:
For patients with renal impairment:
For severe, multiarticular flares:
- Consider combination therapy with oral corticosteroids plus colchicine 2
For limited joint involvement (1-2 large joints):
- Consider intra-articular corticosteroid injection 2
Adjunctive Measures
Important Considerations
- Start treatment as early as possible for best results 2
- If a patient is already on prophylactic colchicine, they can still receive treatment-dose colchicine for an acute flare (1.2 mg followed by 0.6 mg one hour later), then resume prophylactic dose after 12 hours 3
- Do not interrupt urate-lowering therapy during acute flares 2
- IL-1 inhibitors (anakinra, canakinumab) can be considered when first-line agents are contraindicated, ineffective, or poorly tolerated 2